Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Harvard Stem Cell Institute form CureMN Collaboration to Advance ALS Research

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
Strategic partnership established with the Harvard Stem Cell Institute (“HSCI”) to identify compounds that prevent or slow down the loss of motor neurons.

The collaboration “CureMN” (CureMotorNeuron) will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem (“iPS”) cells that were developed by Dr Lee Rubin, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard, and Dr Kevin Eggan, Early Career Scientist at the Howard Hughes Medical Institute, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard as well as Evotec’s leading drug discovery infrastructure and expertise to identify compounds that will have therapeutic value against this life-threatening disease.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Kevin and Lee have made significant contributions to our understanding of the underlying pathology of motor neuron diseases. Their laboratories have developed a large array of ALS patient-derived motor neuron models that allow screening of diseased human cells in culture – an approach that is sometimes referred to as a ‘clinical trial in a dish’. Our intention is to systematically screen for new mechanisms, targets and compounds that have the potential to be developed into new products that will modify and ideally halt the progression of ALS and potentially other motor neuron diseases.”

“Phenotypic screens based on patient-derived iPS cells are an exciting approach to tackle diseases where tractable mechanisms have remained elusive. Evotec’s proven expertise in high-content screening and deep knowledge in the field of motor neurons is a perfect match for this project. In this latest collaborative effort with Evotec, we look forward to putting our combined dedication and knowledge to work identifying new therapeutics for motor neuron diseases”, added Dr Vivian Berlin, Director Business Development in Harvard’s Office of Technology Development.

This agreement marks the third collaboration between Evotec and leading Harvard Stem Cell Institute scientists – and the fourth with Harvard scientists – and significantly expands a partnership model which combines cutting-edge academic research from Harvard with Evotec’s leading drug platform and expertise. This partnership model efficiently and effectively drives the development of innovative drug candidates.

“This agreement is another important step in our vital collaboration with Evotec, enabling us to hasten the transfer of stem cell-based discoveries to the clinic”, said Brock Reeve, Executive Director of HSCI.

“Evotec, HSCI and Harvard share a commitment to accelerating promising research from the lab to the clinic”, says Isaac T. Kohlberg, Harvard University’s Senior Associate Provost and Chief Technology Development Officer. “Our continued collaboration is based upon a shared vision to match world-class science with industrial capability to address important unmet medical need, which is at the core of our public mission.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Achieves Clinical Development Milestone from Bayer
Company announces milestone achieved for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
Thursday, August 04, 2016
Evotec Extends Integrated Drug Discovery Alliance With Genentech
Evotec and Genentech will continue their drug discovery alliance for a further three years.
Tuesday, May 24, 2016
Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec & Facio Partner
Facio partners with Evotec and initiates FSHD drug discovery programme.
Friday, May 08, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec Receives First Milestone in Roche Biomarker Collaboration
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.
Thursday, April 24, 2014
Evotec, Bionamics GmbH Acquisition to accelerate “EVT Innovate” strategy
The acquisition expands discovery pipeline with portfolio of projects especially in Multiple Sclerosis and CNS.
Monday, March 24, 2014
Evotec Enters Integrated Alliance with AstraZeneca
Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.
Monday, October 21, 2013
Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.
Tuesday, July 09, 2013
Evotec AG: New Hormone to Treat Diabetes Published in “Cell”
Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone “betatrophin” that controls beta cell proliferation as potential diabetes treatment.
Friday, April 26, 2013
Evotec Achieves Milestone in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
Evotec receives a milestone payment from Ono for the progression of a compound into pre-clinical development.
Friday, January 11, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!